Skip to main content

ASH Highlights

Meeting Highlights

ASH Highlights, Lymphoma

Durable Responses to CAR T-Cell Therapy in B-Cell Lymphomas

Phoebe Starr, Medical Writer

Meeting Highlights

ASH Highlights, Leukemia

First-Line Ibrutinib Improves Outcomes Compared with Current Standard of Care in Older Patients with CLL

Wayne Kuznar, Medical Writer

ASH Highlights

Initial Results from an Expansion Cohort Receiving Mirvetuximab Soravtansine/Pembrolizumab for Platinum-Resistant Ovarian Cancer: Initial Results from FORWARD II

Meeting Highlights

ASH Highlights

Nivolumab plus Azacitidine Shows Encouraging Activity in R/R AML or as Frontline Therapy in Elderly Patients with AML

Meeting Highlights

ASH Highlights

Safety and Tolerability of Midostaurin from Expanded Treatment Protocol in Patients with FLT3 Mutation–Positive, Newly Diagnosed AML

Meeting Highlights

ASH Highlights

Encouraging Efficacy and Safety with Enasidenib or Ivosidenib plus Azacitidine in Patients with Newly Diagnosed AML

Meeting Highlights

ASH Highlights

Enasidenib Monotherapy Is Well-Tolerated and Active in Older Patients with Untreated mIDH2 AML

ASH Highlights

Triplet Therapy That Includes Elotuzumab Stops Progression of High-Risk Smoldering Multiple Myeloma

ASH Highlights

Obinutuzumab Prolongs Survival in Follicular Lymphoma

ASH Highlights

CAR T-Cell Therapy Succeeds in Aggressive Lymphoma

4
5
6
7

Page 7 of 7
Results 61 - 70 of 70